This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), provides $506,083 to Artificial Axon Labs Inc. (AAL) to develop a novel in vitro myelination assay that models the environment of multiple sclerosis (MS) lesions. The goal is to create a biomimetic 3D-printed drug discovery platform that can directly visualize and quantify myelin wrapping in response to compounds in an MS lesion-like environment. This will address a key challenge in the discovery of remyelinating therapies for MS and other myelin diseases, where current screening methods fail to accurately replicate the inhibitory factors present in demyelinated lesions. By achieving the milestones of developing this assay and validating its efficacy in testing known pro-myelinating compounds, AAL aims to accelerate the discovery of new remyelinating treatments.
Generated 2/25/25, 4:35 AM